PharmaNews
Oncol Res Treat 2021;44:431 –437 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research
Belantamab-Mafodotin er öffnet neue Behandlungsperspektive
Oncol Res Treat 2021;44:428 –429 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research
Mit kombinierter Immuntherapie auf dem Weg zur Heilung?
Oncol Res Treat 2021;44:426 –427 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research
Venetoclax-Kombinationen: Neuer Standard in der AML-Erstlinie
Oncol Res Treat 2021;44:425 –425 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research
Therapiemanagement nach einer CAR-T-Zell-Therapie
Oncol Res Treat 2021;44:XIII –XVI (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research
OnkoImmun 14
Oncol Res Treat 2021;44:I –XII (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research
Vorspann
Oncol Res Treat 2021;44(suppl 1):I –IV (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a < b > < i > ROS1 < /i > < /b > p.L1950F Mutation: Case Report
Conclusion: Our data are the first to show a clinical benefit from targeted treatment with ROS1 TKI in a cancer patient with a thus far undescribedROS1 point mutation without a concomitantROS1 rearrangement. Furthermore, they indicate thatROS1 could be an oncogenic driver in pancreatic cancer. This subgroup could be eligible for targeted treatments, which may contribute to the urgently needed improvement in patient outcome.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 28, 2021 Category: Cancer & Oncology Source Type: research
Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison
Conclusions: FOLFIRINOX is associated with significant survival benefits compared to gem-nab/P and gem-cap. However, it is important to consider the increased grade 3/4 AE risk associated with FOLFIRINOX.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 27, 2021 Category: Cancer & Oncology Source Type: research
Examining the Use of Radiation Therapy for Cholangiocarcinoma: Benefits through Modern Techniques
Conclusion: RT can achieve local control in patients with CCA. Toxicities of RT are manageable but require close clinical and laboratory follow-up.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 21, 2021 Category: Cancer & Oncology Source Type: research
Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation
Conclusions: The outcome of our real-world cohort emphasizes the possible toxic character of the treatment protocol by Ferreri et al. [J Clin Oncol. 2015]. Further improvement in treatment regimens is still an unmet need.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 21, 2021 Category: Cancer & Oncology Source Type: research
Why Do Our Cancer Patients Sleep So Badly? Sleep Disorders in Cancer Patients: A Frequent Symptom with Multiple Causes
Conclusion: Sleep disorders are common in cancer patients. The causes are manifold and should be considered by caregivers during diagnosis, therapy, and aftercare of cancer patients. Tumour patients should actively be asked about sleep disorders. If these are present, they should be addressed, and as they have a large impact on quality of life, treatment options should be offered in cooperation with sleep specialists.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 20, 2021 Category: Cancer & Oncology Source Type: research
Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article
Background: Gastric cancer is a leading cause of cancer-related deaths worldwide. Several treatment possibilities have been investigated, but only a few show clinically meaningful results.Summary: Systemic treatment options for advanced gastric cancer (aGC) have evolved over the recent years, implementing the growing molecular knowledge of this heterogeneous disease. Molecular profiling (at least for HER-2-expression, microsatellite instability status,Epstein-Barr virus expression, and programmed death ligand-1 expression/combined positive score [CPS]) is recommended for all therapy-fit patients prior to the start of a sys...
Source: Oncology Research and Treatment - July 20, 2021 Category: Cancer & Oncology Source Type: research
Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience
Conclusion: Elective discontinuation of CDK4/6 inhibitors is feasible in patients with long-lasting disease stabilization. This strategy should be evaluated in prospective trials.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 19, 2021 Category: Cancer & Oncology Source Type: research
Onkologie und Ökonomie – wie frei sind wir wirklich in der Behandlung von Patient*innen?
Oncol Res Treat 2021;44(suppl 1):1 –25 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - July 16, 2021 Category: Cancer & Oncology Source Type: research
